• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Bristol-Myers, PsiOxus land licensing agreement

December 20, 2016 By Sarah Faulkner

Bristol-Myers, PsiOxus land licensing agreementBristol-Myers Squibb (NYSE:BMY) said today that it landed an exclusive licensing agreement for PsiOxus Therapeutics‘ ‘armed’ oncolytic virus, NG-348, for the treatment of solid tumors.

According to the agreement, Bristol-Myers will pay PsiOxus $50 million upfront and will assume responsibility for global clinical development and commercialization. PsiOxus will be eligible for $886 million in development, regulatory and sales-based milestones. New York-based Bristol-Myers will be responsible for funding the preclinical development of NG-348.

Oncolytic virus therapy makes use of modified viruses that replicate only within tumor cells and stimulate an inflammatory response in the tumor microenvironment. UK-based PsiOxus arms the virus with 2 immuno-therapeutic transgenes using its tumor-specific immuno-gene therapy platform (T-SIGn).

“PsiOxus has developed a novel platform of tumor-targeted delivery with oncolytic viruses focused on cancer and shares our passion for helping more patients respond to treatment,” Bristol-Myers’s head of development for oncology Dr. Fouad Namouni said in prepared remarks. “We are excited to bring our deep expertise in immuno-oncology to the continued development of NG-348 and to better understand the potential role of oncolytic viruses in enhancing checkpoint blockade in multiple types of cancer in the tumor microenvironment.”

In June, the 2 companies collaborated to study PsiOxus’ ‘unarmed’ oncolytic adenovirus therapeutic, enadenotucirev.

“NG-348, represents the first of our T-SIGn armed-viruses,” PsiOxus CEO Dr. John Beadle added. “We are thrilled to partner once again with Bristol-Myers Squibb, a leader in immuno-oncology, to drive this program into clinical development with the aim of providing a potential treatment to cancer patients.”

Filed Under: Clinical Trials, Featured, Immunotherapy, Oncology, Preclinical Trials, Wall Street Beat Tagged With: Bristol-Myers Squibb Co., PsiOxus Therapeutics

IN CASE YOU MISSED IT

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Study backs Tandem automated insulin delivery in pregnant women with type 1 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Abbott could pave new roads in diabetes management with dual sensor on the horizon

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS